Hoth Therapeutics

Hoth Therapeutics ROA

The Return on Assets (ROA) of Hoth Therapeutics (HOTH) as of Nov 3, 2026 is -164.00 %. In the previous year, Return on Assets (ROA) was -106.17 % — a change of 54.47% (lower).

ROA

-164.00 %

YoY

54.47%

Last updated:

In 2025, Hoth Therapeutics's return on assets (ROA) was -164.00 %, a 54.47% increase from the -106.17 % ROA in the previous year.

The Hoth Therapeutics ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-495.23 USD
Jan 1, 2019
-271.29 USD
Jan 1, 2020
-137.29 USD
Jan 1, 2021
-130.30 USD
Jan 1, 2022
-168.24 USD
Jan 1, 2023
-76.59 USD
Jan 1, 2024
-106.17 USD
Jan 1, 2025
-164.00 USD
The Hoth Therapeutics ROA history
YEARROAYoY
-164.00 %+54.47%
-106.17 %+38.61%
-76.59 %-54.47%
-168.24 %+29.12%
-130.30 %-5.09%
-137.29 %-49.39%
-271.29 %-45.22%
-495.23 %+203.19%
-163.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Hoth Therapeutics Stock analysis

What does Hoth Therapeutics do? Hoth Therapeutics, Inc. develops new generation therapies for dermatological disorders and related conditions. The company focuses on products like HT-001 for atopic dermatitis, HT-KIT for mast-cell derived cancers, HT-TBI for traumatic brain injury, and HT-ALZ for neuroinflammatory diseases including Alzheimer’s. It also develops HT-003, HT-004, and HT-002 in preclinical stages, alongside a diagnostic device using mobile technology. The firm targets medical professionals and patients seeking advanced treatments for skin conditions, cancer side effects, and neurological disorders. Hoth Therapeutics generates revenue through the development and eventual commercialization of its therapeutic products. It leverages its pipeline of HT-001, HT-KIT, HT-TBI, and HT-ALZ for dermatological, oncological, and neurological markets. The company also capitalizes on third-party assets, such as a lupus treatment, to expand its portfolio. Its primary customers include healthcare providers and patients requiring innovative solutions for unmet medical needs. The company’s business model centers on advancing its therapeutic pipeline to market readiness, with products targeting high-need areas like cancer side effects, neurological diseases, and inflammatory skin conditions. It relies on partnerships for third-party asset development, such as the lupus treatment, to complement its internal research. Hoth Therapeutics aims to monetize its assets through licensing agreements, product sales, and potential future partnerships in the pharmaceutical sector. Hoth Therapeutics is one of the most popular companies on Eulerpool.

ROA Details

Understanding Hoth Therapeutics's Return on Assets (ROA)

Hoth Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Hoth Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Hoth Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Hoth Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Hoth Therapeutics stock

Return on Assets (ROA) of Hoth Therapeutics is -164.00 % in 2025.

Return on Assets (ROA) of Hoth Therapeutics changed from -106.17 % to -164.00 %, representing a 54.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Hoth Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Hoth Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Hoth Therapeutics

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Hoth Therapeutics